Main > NEPHROLOGY > Transplant Rejection Prevn. > Co: CH. R. DaclizuMAb

---

Co: CH. R. DaclizuMAb's subsections
Company/Licensee
Licensor
Mechanism: IL-2 Receptor Inhibition
Patent>DisClosure
Patent>Total USA No.: 1
Patent>UpDate: 03.13.07
Patent>US Expiration: 09.22.2017
Status: Approved
TradeMark
Web-Site (USA)

Co: CH. R. DaclizuMAb's products
This section has no products